Prosecution Insights
Last updated: October 02, 2026

Myriad Genetics Inc.

Technology area: Biotechnology & Pharmaceuticals

8 pending office actions • 5 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 11 patents granted in the last 365 days

Analysis

Myriad Genetics Inc. has 7 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are spread across 5 distinct art units, suggesting a varied technical focus within the biotech sector. The company is working with 7 distinct examiners, meaning each of the 7 pending office actions is currently assigned to a different individual. This distribution of 7 distinct examiners for 7 pending office actions highlights a completely decentralized prosecution workload. Practitioners should be prepared to manage 7 separate examiner relationships.

The busiest examiner, WHALEY, PABLO S, handles 1 pending office action, which is consistent with the distribution across all 7 distinct examiners. This lack of concentration requires the company to manage 7 separate examiner relationships across 5 distinct art units. Such a distribution indicates that prosecution outcomes are dependent on the individual interpretations of a diverse group of examiners rather than a single primary contact. With 5 distinct art units involved, the company must navigate the specific examination guidelines of several different biotechnology divisions. This profile reflects a highly diversified prosecution effort across multiple examiners and art units.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

8
Total Pending OAs
6
Non-Final OAs
1
Final Rejections
1
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

2
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

6
Hard (75%)
2
Medium (25%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 only1 (12%)
§101 + other4 (50%)
§103 only1 (12%)
Double-patenting + other1 (12%)
Multi-statute (no §101)1 (12%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

7
Life Sciences
88% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
1
Mechanical / Eng
12% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

80 h
Manual time on pending OAs
16 h
Time saved (low, 20%)
28 h
Time saved (mid, 35%)
0.7 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
WHALEY, PABLO S 1 25.1% +21.4%
HORLICK, KENNETH R 1 78.9% +15.3%
HANEY, AMANDA MARIE 1 36.4% +44.9%
MYERS, CARLA J 1 49.3% +46.1%
PHAM, KHAI QUYNH TIEN 1 0.0% +0.0%
BUCHANAN, BAILEY CHEYENNE 1 42.9% +57.1%
ANDERSON-FEARS, KEENAN NEIL 1 12.0% +41.3%
PULLIAM, JOSEPH CONSTANTINE 1 38.1% +31.2%

Hard Cases (7)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.

App #TitleExaminerDue in
19088442 METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITY WHALEY, PABLO S 35d overdue
17353279 METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY HANEY, AMANDA MARIE 4d overdue
17678357 GENE SIGNATURES FOR CANCER PROGNOSIS HORLICK, KENNETH R —
18095386 NON-INVASIVE PRENATAL SAMPLE PREPARATION AND RELATED METHODS AND USES MYERS, CARLA J —
17926566 NUCLEIC ACID SAMPLE ENRICHMENT AND SCREENING METHODS PHAM, KHAI QUYNH TIEN —
17630385 METHOD FOR DETECTING GENETIC VARIATION IN HIGHLY HOMOLOGOUS SEQUENCES BY INDEPENDENT ALIGNMENT AND PAIRING OF SEQUENCE READS ANDERSON-FEARS, KEENAN NEIL —
17111272 COPY NUMBER VARIANT CALLER PULLIAM, JOSEPH CONSTANTINE —

Interview Candidates (7)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.

App #TitleExaminerDue in
19088442 METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITY WHALEY, PABLO S 35d overdue
17353279 METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY HANEY, AMANDA MARIE 4d overdue
17678357 GENE SIGNATURES FOR CANCER PROGNOSIS HORLICK, KENNETH R —
18095386 NON-INVASIVE PRENATAL SAMPLE PREPARATION AND RELATED METHODS AND USES MYERS, CARLA J —
17716381 ENRICHMENT OF CELL-FREE DNA FROM A BIOLOGICAL SAMPLE BUCHANAN, BAILEY CHEYENNE —
17630385 METHOD FOR DETECTING GENETIC VARIATION IN HIGHLY HOMOLOGOUS SEQUENCES BY INDEPENDENT ALIGNMENT AND PAIRING OF SEQUENCE READS ANDERSON-FEARS, KEENAN NEIL —
17111272 COPY NUMBER VARIANT CALLER PULLIAM, JOSEPH CONSTANTINE —

Top Art Units

Art UnitApps
1682 3
1687 2
3619 1
1681 1
1684 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
19088442 METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITY WHALEY, PABLO S 3619 §103§112Other Non-Final OA 35d overdue Pending Mar 24, 2025
17678357 GENE SIGNATURES FOR CANCER PROGNOSIS HORLICK, KENNETH R 1681 §101 Non-Final OA — Pending Feb 23, 2022
17353279 METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY HANEY, AMANDA MARIE 1682 §101§103§112DP Non-Final OA 4d overdue Pending Jun 21, 2021
18095386 NON-INVASIVE PRENATAL SAMPLE PREPARATION AND RELATED METHODS AND USES MYERS, CARLA J 1682 §101§102 Final Rejection — Pending Jan 10, 2023
17926566 NUCLEIC ACID SAMPLE ENRICHMENT AND SCREENING METHODS PHAM, KHAI QUYNH TIEN 1684 §103 Non-Final OA — Pending Nov 18, 2022
17716381 ENRICHMENT OF CELL-FREE DNA FROM A BIOLOGICAL SAMPLE BUCHANAN, BAILEY CHEYENNE 1682 §102§103DP Non-Final OA — Pending Apr 08, 2022
17630385 METHOD FOR DETECTING GENETIC VARIATION IN HIGHLY HOMOLOGOUS SEQUENCES BY INDEPENDENT ALIGNMENT AND PAIRING OF SEQUENCE READS ANDERSON-FEARS, KEENAN NEIL 1687 §101§102§103Other Non-Final OA — Pending Jan 26, 2022
17111272 COPY NUMBER VARIANT CALLER PULLIAM, JOSEPH CONSTANTINE 1687 §101§103§112DP Non-Final OA — Pending Dec 03, 2020

Managing Myriad Genetics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month